Effectiveness of Reminiscence Therapy Versus Cognitive Stimulation in Older Adults With Cognitive Decline

Cognitive Decline Clinical Trial

— TRvsCS  

Official title:

Effectiveness of Reminiscence Therapy Versus Cognitive Stimulation in Older Adults With Cognitive Decline: a Quasi-experimental Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05187572
• Other study ID #: TRvsCS
• Status: Completed
• Phase: N/A
• Start date: April 20, 2017
• Est. completion date: June 6, 2017

Study information

• Verified date: January 2022
• Source: Escola Superior de Enfermagem de Coimbra
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although data suggest that non-pharmacologic therapies such as Reminiscence Therapy (RT) and Cognitive Stimulation (CS) can potentially maintain or reverse this trend, cognitive impairment can be a precursor to neurodegenerative processes. This study aimed to assess how an RT and a CS program affected cognition, depressive symptomatology, and quality of life (QoL) in older persons with cognitive decline who attended community support institutions in central Portugal. For seven weeks, a quasi-experimental study with two arms (RT and CS program) was conducted. The intervention was completed by 76 of the 109 older persons who were first screened (50 in the RT program, 26 in the CS program). In both groups, a pre- and post-intervention analysis revealed statistically significant differences in cognition, particularly in older adults' delayed recall ability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: June 6, 2017
• Est. primary completion date: June 6, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Ability to give informed consent before study commencement;

• Ability to participate in group activities for a period between 45 to 60 minutes;

• No pronounced impairment of their visual and auditory abilities;

• Mild to moderate cognitive decline, assessed as a score equal to or below 20 points in the Six-Item Cognitive Impairment Test (6-CIT).

Exclusion Criteria:

• Unstable clinical condition;

• Prescribed with cholinesterase inhibitors and/or antipsychotics during the study period.

Related Conditions & MeSH terms

• Cognitive Decline
• Cognitive Dysfunction

Intervention

Behavioral:
• Group intervention
This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.

Locations

Country	Name	City	State
Portugal	The Health Sciences Research Unit: Nursing	Coimbra

Sponsors (9)

Lead Sponsor	Collaborator
Paulo Costa	Associação Nacional de Apoio ao Idoso, Centro Social e Paroquial de Carapinheira do Campo, Centro Social Paroquial de Pedrulha, Centro Sociocultural Polivalente de São Martinho, Doce Viver - Residencial Sénior, Bruscos, Junta de Freguesia de Santo António dos Olivais, Obra Social de Torre de Vilela, Santa Casa de Misericórdia de Cantanhede

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in cognition (person with cognitive decline)	Measured using the Montreal Cognitive Assessment (MoCA). Scale scores vary between 0 and 30 points; higher scores correspond to a higher cognition level.	Pre-intervention (baseline)
Primary	Change in depressive dymptomatology (person with cognitive decline)	Measured using the 10-items Geriatric Depression Scale (GDS-10). Scale scores vary between 0 and 10 points; scores equal or above 2 points correspond to a screening diagnosis of depression.	Pre-intervention (baseline)
Primary	Change in quality of life (person with cognitive decline)	Measured using the World Health Organization Quality of Life - module for older adults (WHOQOL-OLD-8). Scale scores vary between 8 and 40 points; higher scores correspond to a higher level of quality of life.	Pre-intervention (baseline)
Primary	Change in cognition (person with cognitive decline)	Measured using the Montreal Cognitive Assessment (MoCA). Scale scores vary between 0 and 30 points; higher scores correspond to a higher cognition level.	8 weeks post baseline
Primary	Change in depressive dymptomatology (person with cognitive decline)	Measured using the 10-items Geriatric Depression Scale (GDS-10). Scale scores vary between 0 and 10 points; scores equal or above 2 points correspond to a screening diagnosis of depression.	8 weeks post baseline
Primary	Change in quality of life (person with cognitive decline)	Measured using the World Health Organization Quality of Life - module for older adults (WHOQOL-OLD-8). Scale scores vary between 8 and 40 points; higher scores correspond to a higher level of quality of life.	Pre-intervention (baseline), 8 weeks post baseline

External Links

•   Project website